Rights statement: © 2015 Head et al. Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Final published version, 692 KB, PDF document
Available under license: CC BY: Creative Commons Attribution 4.0 International License
Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
| Article number | 63 |
|---|---|
| <mark>Journal publication date</mark> | 4/11/2015 |
| <mark>Journal</mark> | Health Research Policy and Systems |
| Issue number | 1 |
| Volume | 13 |
| Number of pages | 7 |
| Publication Status | Published |
| <mark>Original language</mark> | English |
Background: The "Unfinished Agenda" of infectious diseases is of great importance to policymakers and research funding agencies that require ongoing research evidence on their effective management. Journal publications help effectively share and disseminate research results to inform policy and practice. We assess research investments to United Kingdom institutions in HIV, tuberculosis and malaria, and analyse these by numbers of publications and citations and by disease and type of science.
Methods: Information on infection-related research investments awarded to United Kingdom institutions across 1997-2010 were sourced from funding agencies and individually categorised by disease and type of science. Publications were sourced from the Scopus database via keyword searches and filtered to include only publications relating to human disease and containing a United Kingdom-based first and/or last author. Data were matched by disease and type of science categories. Investment (United Kingdom pounds) and publications were compared to generate an 'investment per publication' metric; similarly, an 'investment per citation' metric was also developed as a measure of the usefulness of research.
Results: Total research investment for all three diseases was 1.4 pound billion, and was greatest for HIV (651.4 pound million), followed by malaria (518.7 pound million) and tuberculosis (239.1 pound million). There were 17,271 included publications, with 9,322 for HIV, 4,451 for malaria, and 3,498 for tuberculosis. HIV publications received the most citations (254,949), followed by malaria (148,559) and tuberculosis (100,244). According to UK pound per publication, tuberculosis (50,691) pound appeared the most productive for investment, compared to HIV (61,971) pound and malaria (94,483) pound. By type of science, public health research was most productive for HIV (27,296) pound and tuberculosis (22,273) pound, while phase I-III trials were most productive for malaria (60,491) pound. According to UK pound per citation, tuberculosis (1,797) pound was the most productive area for investment, compared to HIV (2,265) pound and malaria (2,834) pound. Public health research was the most productive type of science for HIV (2,265) pound and tuberculosis (1,797) pound, whereas phase I-III trials were most productive for malaria (1,713) pound.
Conclusions: When comparing total publications and citations with research investment to United Kingdom institutions, tuberculosis research appears to perform best in terms of efficiency. There were more public health-related publications and citations for HIV and tuberculosis than other types of science. These findings demonstrate the diversity of research funding and outputs, and provide new evidence to inform research investment strategies for policymakers, funders, academic institutions, and healthcare organizations.